Loading patent…
AssigneeDistributed Bio, Inc.
InventorsSawsan Youssef, Jacob Glanville
Estimating the term…
Immunotherapeutic compositions including class I MHC component, non-classical MHC class I component, or class II MHC components and methods of use thereof are described. The class I MHC, non-classical class I MHC, class II MHC components can be non-naturally occurring MHC component. Additionally, immunotherapeutic compositions comprising a nucleic acid encoding a deactivated CRISPR-associated nuclease fused to a TET enzyme and a gRNA targeting methylated regions of genetic elements controlling expression of MHC genes and method of use thereof are described. The compositions and methods described herein can further comprise administration of the immunotherapeutic composition with an immune checkpoint inhibitor.
An immunotherapeutic composition, comprising a nucleic acid molecule encoding a first MHC component or a fragment thereof and at least one pharmaceutically acceptable excipient, diluent, or carrier.
-25. (canceled)
The method of claim 27, wherein the MHC component is an HLA with an allele of Table 3.
A method for treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a nucleic acid molecule encoding a major histocompatibility complex (MHC) component or a functional fragment thereof.
(canceled)
-48. (canceled)
(canceled)
(canceled)
(canceled)
An immunotherapeutic composition, comprising:
-79. (canceled)
A method for increasing expression of an MHC gene in a cancer in a subject in need thereof, comprising administering to the subject an immunotherapeutic composition comprising:
-105. (canceled)
-114. (canceled)
-126. (canceled)
A method for treating a cancer in a subject in need thereof, comprising administering to the subject a nucleic acid molecule encoding a regulator of an MHC molecule.
-160. (canceled)
Dependencies are inferred from the claim text.